Clinical Trial Update: Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for CPC634 (CriPec Docetaxel) in platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CPC634 (CriPec Docetaxel)

Snippet

Sponsor: Cristal Therapeutics | Conditions: Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED